Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI107533

Physicochemical and Biological Properties of Human and Canine Plasmins

Y. Takeda and M. Nakabayashi

Department of Medicine, University of Colorado Medical Center, Denver, Colorado 80220

Find articles by Takeda, Y. in: PubMed | Google Scholar

Department of Medicine, University of Colorado Medical Center, Denver, Colorado 80220

Find articles by Nakabayashi, M. in: PubMed | Google Scholar

Published January 1, 1974 - More info

Published in Volume 53, Issue 1 on January 1, 1974
J Clin Invest. 1974;53(1):154–162. https://doi.org/10.1172/JCI107533.
© 1974 The American Society for Clinical Investigation
Published January 1, 1974 - Version history
View PDF
Abstract

Three kinds of plasmin were found to be generated when plasminogen or [125I]plasminogen was incubated at 32°C for longer than 20 min in urokinase and 50% glycerol. Each plasmin was then separated by G-200 or G-75 Sephadex filtration, and its physicochemical properties were determined. The molecular weights of the three plasmins as determined by G-200 Sephadex filtration were 125,000±5,000(SD), 63,000±2,000(SD), and 31,500±1,000(SD), and those by sodium dodecyl sulfate(SDS)-polyacrylamide electrophoresis were 130,000±5,000(SD), 64,000±3,000(SD), and 32,000±1,500(SD). It was also found that during the incubation of the smallest plasmin in SDS and beta-mercaptoethanol it was further split into two smaller pieces of about 16,000 mol wt and that polymer proteins of 95,000±2,000(SD) and 48,000±1,500(SD) mol wt were formed. Despite these differences in the molecular size of the three plasmins, the specific activity of each plasmin was closely similar and in case of human plasmins averaged 29±0.9(SD) CTA units/mg plasmin and in case of canine plasmins 8.5±0.54(SD) CTA units/mg plasmin. Then, using human plasmin of the smallest size (mol wt 31,500), the total plasma antiplasmin capacity was determined in 20 normal human plasma, which averaged 7.8±2(SD) CTA units of plasmin per milliliter plasma. Studies were next made of the affinity of human [125I]-plasmin of the smallest size with albumin, gamma globulin, α2-macroglobulin, α1-antitrypsin, fibrinogen, and fibrin. The results were 0%, 0%, 14.6±0.5(SD)%, 17.6±0.6(SD)%, 21±0.5(SD)%, and 20.5±0.6(SD)%, respectively, of [125I]plasmin available and were unaltered when the amount of [125I]plasmin was increased to twice and four times the original amount. Finally, the plasma disappearance half-life of canine [125I]plasmin of the smallest size was studied in five healthy dogs, which averaged 14.2±0.63(SD) h. These results support the concept that the combination between plasmin and plasmin inhibitors is reversible and indicate that fibrinogen and fibrin have greater affinities than α2-macroglobulin or α1-antitrypsin.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 154
page 154
icon of scanned page 155
page 155
icon of scanned page 156
page 156
icon of scanned page 157
page 157
icon of scanned page 158
page 158
icon of scanned page 159
page 159
icon of scanned page 160
page 160
icon of scanned page 161
page 161
icon of scanned page 162
page 162
Version history
  • Version 1 (January 1, 1974): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts